RIGLRigel Pharmaceuticals, Inc.
What is the market doing?
No clear lean: in an uptrend, but a crowded short (+15% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +31% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RIGL is trading
Rigel Pharmaceuticals, Inc. is +57% over the past year while the S&P 500 is +16%: 41 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +31%
vs 200-day average · a clear uptrend
- RSI (14)
- 52
RSI (14) · neutral
- Below its 52-week high
- 5.5%
Below its 52-week high
Details›
- Last close2026-10-23
- $48.17
- 1 monthS&P 500 −0.94%
- +0.75%
- 1 yearS&P 500 +16%
- +57%
- 5 yearsS&P 500 +86%
- +43%
- vs 50-day average$47.02
- +2.4%
- 52-week high
- $50.96
- 52-week low
- $25.44
- Annualised volatility
- 71%
| Year | Return |
|---|---|
| 2026 (year to date) | +12% |
| 2025 | +155% |
| 2024 | +16% |
| 2023 | −3.3% |
| 2022 | −43% |
| 2021 | −24% |
| 2020 | +64% |
| 2019 | −7.0% |
| 2018 | −41% |
| 2017 | +63% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | −0.93% |
| Feb | 10 | 5 of 10 | +4.7% |
| Mar | 10 | 3 of 10 | −3.8% |
| Apr | 10 | 5 of 10 | −4.6% |
| May | 10 | 3 of 10 | −3.1% |
| Jun | 10 | 4 of 10 | +0.32% |
| Jul | 11 | 6 of 11 | +3.8% |
| Aug | 11 | 8 of 11 | +17% |
| Sep | 11 | 4 of 11 | −1.8% |
| Oct | 11 | 5 of 11 | −4.9% |
| Nov | 10 | 6 of 10 | +22% |
| Dec | 10 | 3 of 10 | +7.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.